As CRISPR-based therapies become ever complex, drug developers urgently need to innovate the analytical tools available to effectively characterize their safety and efficacy profiles and agree upon gold standards moving forward. We are also witnessing increased regulatory scrutiny, with the FDA closely studying off-target analysis conducted ahead of the approval of Casgevy, prior to finalizing guidance on genome editing therapies in January.

To keep up with these growing analytical demands, the 2nd CRISPR-Based Therapy Analytical Development Summit is returning to unite 50+ key figures across Analytical Development, CMC and QC domains, all with the common goal of developing more precise, accurate, and sensitive analytical assays.

Expert discussions will highlight analytical innovation with both traditional and disruptive CRISPR-based therapies, and span in vivo and ex vivo delivery, covering the following core themes:

- Characterization of guides, nucleases, and full drug constructs

- Robust non-clinical and CMC assay development, including biodistribution studies, potency assays, and on-/off- target sequencing detection, nomination, and prediction

-Meeting regulatory expectations for analytical data to successfully support IND submissions

If you are working to develop, characterize, and validate more robust analytical tools to enable the progression of your early R and D work into a clinical therapy, this is your collaborative forum to equip you with the latest innovation, case studies, and actionable insights to level up your analytical efforts.

URLs:

Tickets: https://go.evvnt.com/2433843-2?pid=91 

Brochure: https://go.evvnt.com/2433843-3?pid=91 

Prices:

Drug Developer Pricing - Conference + Workshop Day : USD 4796.00,

Drug Developer Pricing - Conference Only: USD 2999.00,

Academic Pricing - Conference + Workshop Day : USD 4096.00,

Academic Pricing - Conference Only: USD 2599.00,

Solution Provider Pricing - Conference + Workshop Day: USD 5796.00,

Solution Provider Pricing - Conference Only: USD 3699.00

Speakers: Andrew Kernytsky, Principal Consultant, Next Gen Editing, Bryant Chia, Scientist, Analytical Chemistry and Structural Biology, Editas Medicine, Carl Co, Senior Director - Analytical Sciencies, Arbor Biotechnologies, Luca Pinello, Associate Professor, Massachusetts General Hospital and Harvard Medical School, Rachael Cohen, Head of Automation, Laboratory and Operations, Prime Medicine, TJ Cradick, Chief Scientific Officer and Principal Consultant, Gene Editing Frontiers, Yune Kunes, Vice President Head of Analytical Development, Formulation and Early-Stage Quality Control, Prime Medicine, Zack Zhang, Director - Analytical Development, Beam Therapeutics, Ankit Gupta Senior Director, Head Of Gene Editing, Affini-T Therapeutics, Daniel O’Connell, Senior Director, Genomics, Tome Biosciences, Eric Anderson Director, Discovery and Molecular Engineering, Vor Biopharma, Haizi Zheng, Principal Scientist - Bioinformatics, Regeneron Pharmaceuticals Inc, Jie Li, Director, Vertex Pharmaceuticals, Kai-Yuan Chen Director, Data Science and Tech Platform, Scribe Therapeutics, Kok Seong, Lim Senior Director - Analytical Sciences and Quality Control, Metagenomi, Pete Cotter, Director, Molecular Biology and Potency Analytics, Verve Therapeutics, Samantha Maragh, Leader, Genome Editing Program, National Institute of Standards and Technology (NIST), Yuqing Chang, Associate Director, In vivo LNP QC Lead, Beam Therapeutics